Lipella Pharmaceuticals Inc. Common Stock (LIPO) - Total Liabilities
Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has total liabilities worth $862.22K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Lipella Pharmaceuticals Inc. Common Stoc (LIPO) net asset momentum to track the company's year-over-year net asset growth rate.
Lipella Pharmaceuticals Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xeros Technology Group Plc
LSE:XSG
|
UK | GBX1.11 Million |
|
LMS Capital Plc
LSE:LMS
|
UK | GBX1.22 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.48 Million |
|
LEPU MED.T.B. SP.GDR O.N.
F:07Z0
|
Germany | €7.61 Billion |
|
Meyer Burger Tech AG
SW:MBTN
|
Switzerland | CHF545.59 Million |
|
Braime Group PLC
LSE:BMT
|
UK | GBX15.15 Million |
|
Prospex Energy PLC
LSE:PXEN
|
UK | GBX992.70K |
|
Kukbo Co. Ltd.
KO:001140
|
Korea | ₩69.22 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Lipella Pharmaceuticals Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LIPO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipella Pharmaceuticals Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $754.42K | +74.34% |
| 2023-12-31 | $432.73K | -66.05% |
| 2022-12-31 | $1.27 Million | +116.26% |
| 2021-12-31 | $589.34K | +19.86% |
| 2020-12-31 | $491.70K | +107.24% |
| 2019-12-31 | $237.26K | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more